Findings of Research Misconduct, 30846-30847 [2014-12442]
Download as PDF
<![CDATA[
30846
Federal Register / Vol. 79, No. 103 / Thursday, May 29, 2014 / Notices
Department of Health and
Human Services, Hubert H. Humphrey
Building, 200 Independence Avenue
SW., Great Hall, First Floor,
Washington, DC 20201. For a map and
directions to the Hubert H. Humphrey
building, see https://www.hhs.gov/about/
hhh.html.
FOR FURTHER INFORMATION CONTACT: Any
questions about meeting registration or
public comment sign-up should be
directed to CFSAC@
seamoncorporation.com.
Please direct other inquiries to cfsac@
hhs.gov.
SUPPLEMENTARY INFORMATION: CFSAC
was established on September 5, 2002 to
advise, consult with, and make
recommendations to the Secretary,
through the Assistant Secretary for
Health, on a broad range of topics
including: (1) The current state of
knowledge and research and the
relevant gaps in knowledge and research
about the epidemiology, etiologies,
biomarkers, and risk factors relating to
myalgic encephalomyelitis/chronic
fatigue syndrome (ME/CFS), and
identifying potential opportunities in
these areas; (2) impact and implications
of current and proposed diagnosis and
treatment methods for ME/CFS; (3)
development and implementation of
programs to inform the public, health
care professionals, and the biomedical
research communities about ME/CFS
advances; and (4) strategies to improve
the quality of life of ME/CFS patients.
The agenda for this meeting is being
developed and will be posted on the
CFSAC Web site, https://www.hhs.gov/
advcomcfs/ when finalized. The
meeting will be live-video streamed at
https://www.hhs.gov/live and archived
through the CFSAC Web site: https://
www.hhs.gov/advcomcfs/. Listeningonly via telephone will be available on
both days. Call-in information will be
posted on the CFSAC Web site.
Individuals who plan to attend inperson should register at https://
www.blsmeetings.net/CFSAC. All
registration should be completed by
June 12, 2014. Attendance by visitors
who are not U.S. citizens is welcome,
but prior approval is required by
sending a request to CFSAC@
seamoncorporation.com before June 5,
2014. Members of the media will also
need to register. All attendees will be
required to show valid governmentissued picture identification (state or
federal) for entry into the federal
building. Non-federal employees will
receive a wrist band that must be worn
the entire time. Security requires all
non-federal employees to be escorted
the entire time they are in the building.
tkelley on DSK3SPTVN1PROD with NOTICES
ADDRESSES:
VerDate Mar<15>2010
17:19 May 28, 2014
Jkt 232001
Upon leaving the building for any
reason, persons will be required to
follow the security steps mentioned
above and receive a new wrist band.
Members of the public will have the
opportunity to provide public comment
at the meeting or via telephone.
International calls cannot be
accommodated. You are no longer
required to submit a written copy of
your testimony unless you wish to have
it included in the public record.
Individuals wishing to provide public
comment in-person or via phone will be
required to request time for public
comment by Monday, June 9, 2014, at
the following link: https://
www.blsmeetings.net/CFSAC. An email
to acknowledge receipt of the request for
public comment will be sent from
CFSAC@seamoncorporaton.com.
Another email will be sent by June 12,
2014, to confirm the time that has been
given to each individual who is
scheduled to provide public comment.
Each speaker will be limited to three
minutes for public comment. No
exceptions will be made. Priority will be
given to individuals who have not
provided public comment within the
previous year.
Individuals wishing to submit written
comment for the public record should
send an electronic copy of their written
testimony to: CFSAC@seamon
corporation.com by June 12, 2014. The
document for public record must not
exceed 5 single-spaced, typed pages,
using a 12-point typeface; it is preferred
that the document be prepared in the
MS Word format. Please note that PDF
files, handwritten notes, charts, and
photographs will not be posted on the
CFSAC Web site, but will be available
upon request at CFSAC@seamon
corporation.com and for public view
during the CFSAC meeting at the Hubert
H. Humphrey Building, Department of
Health and Human Services, 200
Independence Ave. SW., Great Hall,
Washington, DC 20201.
Requests to participate in the public
comment session and provide written
testimony will not be accepted through
the CFSAC email account. Please send
all questions about specific public
comment requests or inquiries to
CFSAC@seamoncorporation.com.
Only written testimony submitted for
public record and received in advance
of the meeting are part of the official
meeting record and will be posted to the
CFSAC Web site. Materials submitted
should not include sensitive personal
information, such as social security
number, birthdate, driver’s license
number, state identification or foreign
country equivalent, passport number,
financial account number, credit or
PO 00000
Frm 00043
Fmt 4703
Sfmt 4703
debit card number. If you wish to
remain anonymous the document must
specify this.
Persons who wish to distribute
printed materials in person to CFSAC
members should submit one copy to the
Designated Federal Officer at cfsac@
hhs.gov, prior to June 12, 2014.
Dated: May 16, 2014.
Nancy C. Lee,
Designated Federal Officer, Chronic Fatigue
Syndrome Advisory Committee.
[FR Doc. 2014–12371 Filed 5–28–14; 8:45 am]
BILLING CODE 4150–28–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Office of the Secretary
Findings of Research Misconduct
Office of the Secretary, HHS.
Notice.
AGENCY:
ACTION:
Notice is hereby given that
the Office of Research Integrity (ORI)
has taken final action in the following
case:
Helen Freeman, Ph.D., Harvard
Medical School and Beth Israel
Deaconess Medical Center: Based on an
investigation conducted by Harvard
Medical School (HMS) and Beth Israel
Deaconess Medical Center (BIDMS) and
additional analysis conducted by ORI in
its oversight review, ORI found that Dr.
Helen Freeman, former HMS
Postdoctoral Fellow at BIDMS, engaged
in research misconduct in research
supported by National Institute of
Diabetes and Digestive and Kidney
Diseases (NIDDK), National Institutes of
Health (NIH), grant R37 DK053477.
ORI found that the Respondent
engaged in research misconduct by
knowingly and intentionally falsifying
three (3) figures and/or legends and one
(1) supplemental movie legend in a
manuscript submitted for publication to
the journal Nature (Freeman, H.C.,
Kong, D., Sidman, R.L., & Lowell, B.
‘‘Inhibition of UCP2 Prevents
Neurodegenerative Diseases in Mice.’’).
Specifically, ORI found that
Respondent:
• Falsified Figure 6 and its legend in
a manuscript submitted to Nature by
claiming that the experiment
represented histological and rotarod
results from 5 week old pcd3J-/- mice
treated with saline or pcd3J-/- mice
treated with genipin when the genotype,
treatment conditions, numbers of mice
used, and mice age were not as claimed;
these falsified data also were presented
to a colleague for use in related
experiments
SUMMARY:
E:\FR\FM\29MYN1.SGM
29MYN1
Federal Register / Vol. 79, No. 103 / Thursday, May 29, 2014 / Notices
• falsified Figure 4, Supplementary
Figure 3, and Supplementary Movie 1
and/or its legends in a manuscript
submitted to Nature by claiming that the
knockout of UCP2 rescues the ataxic
phenotype of pcd3J-/- mice when she
knew this to be false.
•
Dr. Freeman has voluntarily agreed
for a period of three (3) years, beginning
on May 6, 2014:
(1) To have her research supervised if
employed by an institution that receives
or applies for U.S. Public Health Service
(PHS) funding; Respondent agreed that
prior to the submission of an
application for PHS support for a
research project on which the
Respondent’s participation is proposed
and prior to Respondent’s participation
in any capacity on PHS-supported
research, Respondent shall ensure that a
plan for supervision of Respondent’s
duties is submitted to ORI for approval;
the supervision plan must be designed
to ensure the scientific integrity of
Respondent’s research contribution;
Respondent agreed that she shall not
participate in any PHS-supported
research until such a supervision plan is
submitted to and approved by ORI;
Respondent agreed to maintain
responsibility for compliance with the
agreed-upon supervision plan;
(2) that any institution employing her
shall submit, in conjunction with each
application for PHS funds, or report,
manuscript, or abstract involving PHSsupported research in which
Respondent is involved, a certification
to ORI that the data provided by
Respondent are based on actual
experiments or are otherwise
legitimately derived and that the data,
procedures, and methodology are
accurately reported in the application,
report, manuscript, or abstract; and
(3) to exclude herself voluntarily from
serving in any advisory capacity to PHS
including, but not limited to, service on
any PHS advisory committee, board,
and/or peer review committee, or as a
consultant.
FOR FURTHER INFORMATION CONTACT:
tkelley on DSK3SPTVN1PROD with NOTICES
Acting Director, Office of Research
Integrity, 1101 Wootton Parkway, Suite
VerDate Mar<15>2010
17:19 May 28, 2014
Jkt 232001
750, Rockville, MD 20852, (240) 453–
8800.
Donald Wright,
Acting Director, Office of Research Integrity.
[FR Doc. 2014–12442 Filed 5–28–14; 8:45 am]
BILLING CODE 4150–31–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Agency for Healthcare Research and
Quality
Agency Information Collection
Activities: Proposed Collection;
Comment Request
Agency for Healthcare Research
and Quality, HHS.
ACTION: Notice.
AGENCY:
This notice announces the
intention of the Agency for Healthcare
Research and Quality (AHRQ) to request
that the Office of Management and
Budget (OMB) approve the proposed
information collection project:
‘‘Voluntary Customer Survey Generic
Clearance for the Agency for Healthcare
Research and Quality.’’ In accordance
with the Paperwork Reduction Act, 44
U.S.C. 3501–3520, AHRQ invites the
public to comment on this proposed
information collection.
DATES: Comments on this notice must be
received by July 28, 2014.
ADDRESSES: Written comments should
be submitted to: Doris Lefkowitz,
Reports Clearance Officer, AHRQ, by
email at doris.letkowitz@AHRQ.hhs.gov.
Copies of the proposed collection
plans, data collection instruments, and
specific details on the estimated burden
can be obtained from the AHRQ Reports
Clearance Officer.
FOR FURTHER INFORMATION CONTACT:
Doris Lefkowitz, AHRQ Reports
Clearance Officer, (301) 427–1477, or by
email at doris.lefkowitz@AHRQ.hhs.gov.
SUPPLEMENTARY INFORMATION:
SUMMARY:
Proposed Project
Voluntary Customer Survey Generic
Clearance for the Agency for Healthcare
Research and Quality
This is a request for the Office of
Management and Budget (OMB) to reapprove for an additional 3 years, under
the Paperwork Reduction Act of 1995,
PO 00000
Frm 00044
Fmt 4703
Sfmt 4703
30847
the generic clearance for the Agency for
Healthcare Research and Quality
(AHRQ) to survey the users of AHRQ’s
work products and services, OMB
control number 0935–0106. The current
clearance was approved on July 20th,
2011 and will expire on July 31st, 2014.
Customer surveys will be undertaken
by AHRQ to assess its work products
and services provided to its customers,
to identify problem areas, and to
determine how they can be improved.
Surveys conducted under this generic
clearance are not required by regulation
and will not be used by AHRQ to
regulate or sanction its customers.
Surveys will be entirely voluntary, and
information provided by respondents
will be combined and summarized so
that no individually identifiable
information will be released. Proposed
information collections submitted under
this generic clearance will be reviewed
and acted upon by OMB within 14 days
of submission to OMB.
Method of Collection
The information collected through
focus groups and voluntary customer
surveys will be used by AHRQ to
identify strengths and weaknesses in
products and services to make
improvements that are practical and
feasible. Information from these
customer surveys will be used to plan
and redirect resources and efforts to
improve or maintain a high quality of
service to the lay and health
professional public.
Estimated Annual Respondent Burden
Exhibit 1 shows the estimated total
burden hours for the respondents. Mail
surveys are estimated to average 15
minutes, telephone surveys 40 minutes,
web-based surveys 10 minutes, focus
groups two hours, and in-person
interviews are estimated to average 50
minutes. Mail surveys may also be sent
to respondents via email, and may
include a telephone non-response
follow-up. Telephone non-response
follow-up for mailed surveys does not
count as a telephone survey. The total
burden hours for the 3 years of the
clearance is estimated to be 10,150
hours.
Exhibit 2 shows the estimated cost
burden for the respondents. The total
cost burden for the 3 years of the
clearance is estimated to be $340,127.
E:\FR\FM\29MYN1.SGM
29MYN1
]]>Agencies
[Federal Register Volume 79, Number 103 (Thursday, May 29, 2014)]
[Notices]
[Pages 30846-30847]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2014-12442]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Office of the Secretary
Findings of Research Misconduct
AGENCY: Office of the Secretary, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: Notice is hereby given that the Office of Research Integrity
(ORI) has taken final action in the following case:
Helen Freeman, Ph.D., Harvard Medical School and Beth Israel
Deaconess Medical Center: Based on an investigation conducted by
Harvard Medical School (HMS) and Beth Israel Deaconess Medical Center
(BIDMS) and additional analysis conducted by ORI in its oversight
review, ORI found that Dr. Helen Freeman, former HMS Postdoctoral
Fellow at BIDMS, engaged in research misconduct in research supported
by National Institute of Diabetes and Digestive and Kidney Diseases
(NIDDK), National Institutes of Health (NIH), grant R37 DK053477.
ORI found that the Respondent engaged in research misconduct by
knowingly and intentionally falsifying three (3) figures and/or legends
and one (1) supplemental movie legend in a manuscript submitted for
publication to the journal Nature (Freeman, H.C., Kong, D., Sidman,
R.L., & Lowell, B. ``Inhibition of UCP2 Prevents Neurodegenerative
Diseases in Mice.'').
Specifically, ORI found that Respondent:
Falsified Figure 6 and its legend in a manuscript
submitted to Nature by claiming that the experiment represented
histological and rotarod results from 5 week old pcd3J-/-
mice treated with saline or pcd3J-/- mice treated with
genipin when the genotype, treatment conditions, numbers of mice used,
and mice age were not as claimed; these falsified data also were
presented to a colleague for use in related experiments
[[Page 30847]]
falsified Figure 4, Supplementary Figure 3, and
Supplementary Movie 1 and/or its legends in a manuscript submitted to
Nature by claiming that the knockout of UCP2 rescues the ataxic
phenotype of pcd3J-/- mice when she knew this to be false.
Dr. Freeman has voluntarily agreed for a period of three (3) years,
beginning on May 6, 2014:
(1) To have her research supervised if employed by an institution
that receives or applies for U.S. Public Health Service (PHS) funding;
Respondent agreed that prior to the submission of an application for
PHS support for a research project on which the Respondent's
participation is proposed and prior to Respondent's participation in
any capacity on PHS-supported research, Respondent shall ensure that a
plan for supervision of Respondent's duties is submitted to ORI for
approval; the supervision plan must be designed to ensure the
scientific integrity of Respondent's research contribution; Respondent
agreed that she shall not participate in any PHS-supported research
until such a supervision plan is submitted to and approved by ORI;
Respondent agreed to maintain responsibility for compliance with the
agreed-upon supervision plan;
(2) that any institution employing her shall submit, in conjunction
with each application for PHS funds, or report, manuscript, or abstract
involving PHS-supported research in which Respondent is involved, a
certification to ORI that the data provided by Respondent are based on
actual experiments or are otherwise legitimately derived and that the
data, procedures, and methodology are accurately reported in the
application, report, manuscript, or abstract; and
(3) to exclude herself voluntarily from serving in any advisory
capacity to PHS including, but not limited to, service on any PHS
advisory committee, board, and/or peer review committee, or as a
consultant.
FOR FURTHER INFORMATION CONTACT: Acting Director, Office of Research
Integrity, 1101 Wootton Parkway, Suite 750, Rockville, MD 20852, (240)
453-8800.
Donald Wright,
Acting Director, Office of Research Integrity.
[FR Doc. 2014-12442 Filed 5-28-14; 8:45 am]
BILLING CODE 4150-31-P
